Cilostazol could inhibit the activation of NLRP3 inflammasome in endothelial cells, thereby inhibiting the production of IL‐1β and IL‐18, suggesting it could reduce adverse vascular reactions and treat endothelial dysfunction in DM patients.240. This evidence concerns the gene IL1B and diabetes mellitus.